Clinical Trial

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a phase 2 open-label, single-center clinical study to evaluate the efficacy and safety SKB264 in combination with toripalimab in patients with unresectable stage III non-small cell lung cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-23; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT06706219
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non Small Cell Lung Cancer (Stage III)
Enrollment 50 participants
Start Date 2026-05-10
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-03